Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

Pembrolizumab plus chemotherapy followed by pembrolizumab-olaparib maintenance significantly improves progression-free survival in patients with advanced BRCA non-mutated epithelial ovarian cancer, with a hazard ratio of 0.66.

• Why it matters: This work addresses the lack of effective first-line maintenance options for patients with BRCA non-mutated ovarian cancer, a group with limited targeted therapies and poorer outcomes.
• What they did: A randomized, double-blind phase 3 trial involving 1367 women across 22 countries tested pembrolizumab with chemotherapy, followed by maintenance with pembrolizumab-olaparib or placebo, measuring progression-free survival as the primary endpoint.
• The result: Pembrolizumab-olaparib maintenance extended progression-free survival compared to control, with manageable adverse events, indicating potential for improved treatment strategies in this patient population.